SUBSCRIBE
SUBSCRIBE
News   Drug Development

Isis Pharmaceuticals, Inc. Discusses its New ISIS 301012 Phase 2 Clinical Data Presented at the DALM Symposium

October 1, 2007 | 
1 min read

CARLSBAD, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS - News) announces the following webcast:

Clinical research Phase II
MORE ON THIS TOPIC
Recession arrow, Graph showing business decline on led screen
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
December 20, 2024
 · 
1 min read
 · 
Kate Goodwin
GSK's headquarters office building in Poznan, Poland
Ovarian cancer
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
December 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Corporate headquarters of Novo Nordisk in Denmark
Obesity
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
December 20, 2024
 · 
3 min read
 · 
Tristan Manalac
Roche's signage at its office in France
Parkinson’s disease
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
December 19, 2024
 · 
1 min read
 · 
Annalee Armstrong